The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Studies of Cognitive Change in Patients With Schizophrenia Following Novel Antipsychotic Treatment
Abstract
OBJECTIVE: Novel antipsychotic medications have been reported to have beneficial effects on cognitive functioning in patients with schizophrenia. However, these effects have been assessed in studies with considerable variation in methodology. A large number of investigator-initiated and industry-sponsored clinical trials are currently underway to determine the effect of various novel antipsychotics on cognitive deficits in patients with schizophrenia. The ability to discriminate between high- and low-quality studies will be required to understand the true implications of these studies and their relevance to clinical practice. METHOD: This article addresses several aspects of research on cognitive enhancement in schizophrenia, emphasizing how the assessment of cognitive function in clinical trials requires certain standards of study design to lead to interpretable results. RESULTS: Novel antipsychotic medications appear to have preliminary promise for the enhancement of cognitive functioning. However, the methodology for assessing the treatment of cognitive deficits is still being developed. CONCLUSIONS: Researchers and clinicians alike need to approach publications in this area with a watchful eye toward methodological weaknesses that limit the interpretability of findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033430 · Cited by 2,999
Wisconsin Card Sorting Test Manual – Revised and Expanded
Heaton, R. K., Chelune, C., Talley, J., Kay, G., & Curtiss, G. (1981) · Medical Entomology and Zoology · Cited by 2,987
Relation of sample size to the stability of component patterns.
Guadagnoli, E., & Velicer, W. F. (1988) · Psychological Bulletin · doi:10.1037/0033-2909.103.2.265 · Cited by 2,880
Farde, L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820070032005 · Cited by 1,419
Risperidone in the treatment of schizophrenia
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.6.825 · Cited by 1,193
The Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia
Meltzer, H. Y., & McGurk, S. R. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033376 · Cited by 1,020
Olanzapine versus Placebo and Haloperidol
Beasley, C. M., Tollefson, G., Tran, P., Satterlee, W., Sanger, T., & Hamilton, S. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00069-p · Cited by 778
Keefe, R. S. E., Silva, S. G., Perkins, D. O., & Lieberman, J. A. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033374 · Cited by 693
Self-citation
Cited by
Keefe, R. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2003.09.011 · Cited by 1,573
Neurocognition in first-episode schizophrenia: a meta-analytic review.
Mesholam-Gately, R. I., Giuliano, A. J., Goff, K. P., Faraone, S. V., & Seidman, L. J. (2009) · Neuropsychology · doi:10.1037/a0014708 · Cited by 1,130
Keefe, R. S. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.633 · Cited by 1,065
Self-citationClinical Practice Recommendations
Fowler, M. J. (2011) · Clinical Diabetes · doi:10.2337/diaclin.29.4.163 · Cited by 995
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Green, M. F., Nuechterlein, K. H., Gold, J. M., Barch, D. M., Cohen, J., Essock, S., Fenton, W. S., Frese, F., Goldberg, T. E., Heaton, R. K., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.06.023 · Cited by 919
Self-citationMueser, K. T., & McGurk, S. R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16458-1 · Cited by 876
Serotonin receptors : their key role in drugs to treat schizophrenia
Meltzer, H. Y., Li, Z., Kaneda, Y., & Ichikawa, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.010 · Cited by 775
Cognitive deficits and functional outcome in schizophrenia
Bowie, C. R., & Harvey, P. D. (2006) · Neuropsychiatric Disease and Treatment · doi:10.2147/nedt.2006.2.4.531 · Cited by 647
Self-citationHasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Nonsocial and social cognition in schizophrenia: current evidence and future directions
Green, M. F., Horan, W. P., & Lee, J. (2019) · World Psychiatry · doi:10.1002/wps.20624 · Cited by 612
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Woodward, N. D., Purdon, S. E., Meltzer, H. Y., & Zald, D. H. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570500516x · Cited by 605
Genes, dopamine and cortical signal-to-noise ratio in schizophrenia
Winterer, G., & Weinberger, D. R. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.08.002 · Cited by 600
Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 573
Bilder, R. M., Goldman, R. S., Volavka, J., Czobor, P., Hoptman, M., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J., Kunz, M., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1018 · Cited by 538
Cognitive Control Deficits in Schizophrenia: Mechanisms and Meaning
Lesh, T. A., Niendam, T. A., Minzenberg, M. J., & Carter, C. S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.156 · Cited by 506
Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial
Keefe, R. S. E., Bilder, R. M., Harvey, P. D., Davis, S. M., Palmer, B. W., Gold, J. M., Meltzer, H. Y., Green, M. F., Miller, D. D., Canive, J. M., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301072 · Cited by 472
“…the CATIE neurocognitive variables, and since previous work on the effect of antipsychotic medications on cognition suggests that some domains may demonstrate more improvement than others (Harvey and Keefe, 2001; Woodward et al, 2005), secondary analyses will focus on the five domain scores.”
BackgroundSelf-citationCognitive Impairment in Schizophrenia
Keefe, R. S. E., & Harvey, P. D. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-25758-2_2 · Cited by 472
Self-citationBuchanan, R. W. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi020 · Cited by 438
Update on Typical and Atypical Antipsychotic Drugs
Meltzer, H. Y. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-050911-161504 · Cited by 433
Modern antipsychotic drugs: a critical overview
Gardner, D. M. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041064 · Cited by 422
Marder, S. R., & Fenton, W. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.09.010 · Cited by 421
Andrews, S. C., Hoy, K. E., Enticott, P. G., Daskalakis, Z. J., & Fitzgerald, P. B. (2011) · Brain Stimulation · doi:10.1016/j.brs.2010.06.004 · Cited by 418
Generalized and Specific Neurocognitive Deficits in Prodromal Schizophrenia
Lencz, T., Smith, C. W., McLaughlin, D., Auther, A., Nakayama, E., Hovey, L., & Cornblatt, B. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.005 · Cited by 402
Defining a cognitive function decrement in schizophrenia
Keefe, R. S. E., Eesley, C. E., & Poe, M. P. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.01.003 · Cited by 389
Self-citationSchizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.025 · Cited by 385
Barnes, T. R., & the Schizophrenia Consensus Group of the British Association for Psychopharmacology (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 356
Cognitive deficits as treatment targets in schizophrenia
Gold, J. M. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.09.008 · Cited by 354
Cirillo, M. A., & Seidman, L. J. (2003) · Neuropsychology Review · doi:10.1023/a:1023870821631 · Cited by 341
The primacy of cognition in schizophrenia
Heinrichs, R. W. (2005) · American Psychologist · doi:10.1037/0003-066x.60.3.229 · Cited by 338
Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder
Lewandowski, K. E., Cohen, B. M., & Öngur, D. (2011) · Psychological Medicine · doi:10.1017/s0033291710001042 · Cited by 336
A Review of Cognitive Training in Schizophrenia
Twamley, E. W., Jeste, D. V., & Bellack, A. S. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007011 · Cited by 335
Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H.-J., WFSBP Task Force on Treatment Guide, Falkai, P., Wobrock, T., Lieberman, J., et al. (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970500483177 · Cited by 331
Longitudinal studies of cognition in schizophrenia: Meta-analysis
Szöke, A., Trandafir, A., Dupont, M.-E., Méary, A., Schürhoff, F., & Leboyer, M. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.029009 · Cited by 331
Meltzer, H. Y., Arvanitis, L., Bauer, D., Rein, W., & Meta-Trial Study Group (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.975 · Cited by 330
Davidson, M., Galderisi, S., Weiser, M., Werbeloff, N., Fleischhacker, W. W., Keefe, R. S., Boter, H., Keet, I. P. M., Prelipceanu, D., Rybakowski, J. K., et al. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08060806 · Cited by 320
Self-citationWhat Do We Know About Neuropsychological Aspects Of Schizophrenia?
Palmer, B. W., Dawes, S. E., & Heaton, R. K. (2009) · Neuropsychology Review · doi:10.1007/s11065-009-9109-y · Cited by 316
Keefe, R. S. E., Seidman, L. J., Christensen, B. K., Hamer, R. M., Sharma, T., Sitskoorn, M. M., Lewine, R. R. J., Yurgelun-Todd, D. A., Gur, R. C., Tohen, M., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.985 · Cited by 314
Self-citationMishara, A. L., & Goldberg, T. E. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.01.027 · Cited by 310
Cognitive dysfunction in bipolar disorder and schizophrenia: a systematic review of meta-analyses
Carvalho, A. F., Bortolato, B., Miskowiak, K., Vieta, E., & Köhler, C. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s76700 · Cited by 306
Young, J. W., Powell, S. B., Risbrough, V., Marston, H. M., & Geyer, M. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.02.004 · Cited by 298
Towards a muscarinic hypothesis of schizophrenia
Raedler, T. J., Bymaster, F. P., Tandon, R., Copolov, D., & Dean, B. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001924 · Cited by 291
Vigen, C. L. P., Mack, W. J., Keefe, R. S. E., Sano, M., Sultzer, D. L., Stroup, T. S., Dagerman, K. S., Hsiao, J. K., Lebowitz, B. D., Lyketsos, C. G., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.08121844 · Cited by 281
Self-citationCognition in Schizophrenia: Impairments, Determinants, and Functional Importance
Bowie, C. R., & Harvey, P. D. (2005) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2005.05.004 · Cited by 280
Self-citationKeefe, R. S. E., Sweeney, J. A., Gu, H., Hamer, R. M., Perkins, D. O., McEvoy, J. P., & Lieberman, J. A. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1061 · Cited by 276
Self-citationTandon, R., Belmaker, R. H., Gattaz, W. F., Lopez-Ibor, J. J., Okasha, A., Singh, B., Stein, D. J., Olie, J.-P., Fleischhacker, W. W., & Moeller, H.-J. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.11.033 · Cited by 276
Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H.-J., WFSBP Task Force on Treatment Guidelines for Schizophrenia, Falkai, P., Wobrock, T., Lieberman, J., et al. (2005) · The World Journal of Biological Psychiatry · doi:10.1080/15622970510030090 · Cited by 269
Integrated Psychological Therapy (IPT) for Schizophrenia: Is It Effective?
Roder, V. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl021 · Cited by 265
The Cognitive Neuroscience of Memory Function and Dysfunction in Schizophrenia
Ranganath, C., Minzenberg, M. J., & Ragland, J. D. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.011 · Cited by 263
Processing Speed Deficits in Schizophrenia: Reexamining the Evidence
Knowles, E. E. M., David, A. S., & Reichenberg, A. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09070937 · Cited by 261
Cognition in schizophrenia: Past, present, and future
Green, M. F., & Harvey, P. D. (2014) · Schizophrenia Research: Cognition · doi:10.1016/j.scog.2014.02.001 · Cited by 258
Self-citationBarch, D. M., & Carter, C. S. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.12.019 · Cited by 222
Harvey, P. D., Rabinowitz, J., Eerdekens, M., & Davidson, M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1888 · Cited by 161
Self-citationLlado-Pelfort, L., Santana, N., Ghisi, V., Artigas, F., & Celada, P. (2012) · Cerebral Cortex · doi:10.1093/cercor/bhr220 · Cited by 156
KUROKI, T., NAGAO, N., & NAKAHARA, T. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00910-2 · Cited by 146
The brief assessment of cognition in schizophrenia. Normative data for the Italian population
Anselmetti, S., Poletti, S., Ermoli, E., Bechi, M., Cappa, S., Venneri, A., Smeraldi, E., & Cavallaro, R. (2008) · Neurological Sciences · doi:10.1007/s10072-008-0866-9 · Cited by 129
Achim, A. M., Ouellet, R., Roy, M.-A., & Jackson, P. L. (2011) · Psychiatry Research · doi:10.1016/j.psychres.2010.10.030 · Cited by 128
Xu, H. (2010) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2010.00008 · Cited by 108
An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia
Shiina, A., Kanahara, N., Sasaki, T., Oda, Y., Hashimoto, T., Hasegawa, T., Yoshida, T., Iyo, M., & Hashimoto, K. (2015) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2015.13.1.62 · Cited by 107
Mirjana, C., Baviera, M., Invernizzi, R. W., & Balducci, C. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300479 · Cited by 102
Acheson, D. T., Twamley, E. W., & Young, J. W. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00103 · Cited by 26
Implementation considerations for multisite clinical trials with cognitive neuroscience tasks
Keefe, R. S. E., & Harvey, P. D. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn042 · Cited by 24
Carli, M., Calcagno, E., Mainini, E., Arnt, J., & Invernizzi, R. W. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2066-6 · Cited by 20
Pharmacological Treatment of Cognitive Dysfunction in Neuropsychiatric Disorders
Venero, C. (2015) · Cognitive Enhancement · doi:10.1016/b978-0-12-417042-1.00010-3 · Cited by 4
Metadata
- Authors
- Harvey, P. D., & Keefe, R. S. E.
- Venue
- American Journal of Psychiatry
- Published
- 2001-02-01
- Volume
- 158
- Issue
- 2
- Pages
- 176-184
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2128164348
- Cited by
- 620
- References
- 54
- FWCI
- 24.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.